PET Assessment of Acute Lung Transplant Rejection

• Status: Terminated
• Trial end date: 2017-02-04
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to gain understanding of the basic responses of the lungs to inflammation and specifically if there may be a better way to detect graft inflammation using non-invasive methods as well as to determine the effectiveness of immunosuppressive treatment regimens in preventing acute rejection in lung transplant recipients.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Washington University School of Medicine
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Fluorodeoxyglucose F18

Criteria

Inclusion Criteria:

• Double-lung transplant recipient

• Scheduled for bronchoscopy with transbronchial biopsy

• Capable of lying still and supine with arms raised above the head within the PET/CT scanner for ~1.25 hours

• Capable of following instructions for breathing protocol during CT portion of PET/CT

• Able and willing to give informed consent

• BMI < 35

• Already scheduled to undergo bronchoscopy with bronchoalveolar lavage (BAL) for clinical reasons

• Willing to donate a portion of BAL and biopsy specimen for laboratory testing

Exclusion Criteria:

• Glucose level > 150 mg/dl at time of [18F]FDG PET scan (however, up to 160 mg/dl, with repeat testing showing level is stable or decreasing, is acceptable)

• Pregnancy (confirmed by qualitative urine human chorionic gonadotropin (hCG) pregnancy test)

• Lactation

• Presence of implanted electronic medical device

• Enrollment in another research study of an investigational drug

• Inability to lie flat with arms raised above the head for 1.5 hours for PET/CT scans or follow breathing protocol instructions for the CT portion of the PET/CT